COVID play- $ARFXF ProMIS Neurosciences just announced commercialization of its highly selective and specific serology test for COVID antibodies.
It can measure your response to infection or vaccination and the level of immunity you have to the different variants.
The company market cap is $50M. The annual COVID serology test market is in the $1-2B range. There are some competitors out there, but a lot of the products on the market are crap. So their market penetration could be high.
This company also has some awesome products in the pipe of Alzheimer's treatment, and that market is massive and largely unmet.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.